newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

- Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate MYMD-1® - MyMD